The Costs and Valuation of Health Impacts of Measles and Rubella Risk Management Policies

摘要: National and global health policymakers require good information about the costs benefits of their investments in measles rubella immunization programs. Building on our review existing economics literature, we develop inputs for use regional models expected future vaccination, treatment, surveillance, other coordination activities. Given diversity world limited data, characterize countries according to 2013 World Bank income levels using U.S. dollars (2013$US). We estimate that routine supplemental activities will cost governments donors over 2013$US 2.3 billion per year foreseeable future, with high-income accounting 55% costs, vaccinate birth cohorts approximately 134 million surviving infants protect population 7 people. find significantly higher consequences or disease than vaccine use, disability-adjusted life (DALY) loss case generally at least 100 times dose. To support estimates economic and/or elimination control, probabilities various sequelae infections adverse events, DALY outcomes, associated treatment costs. Managing achieve goals objectives Global Vaccine Action Plan an ongoing commitment financial resources prevent outcomes save